Insulin Pump Reliability and Durability Patent Landscape 2026
- Filing activity is still climbing. the 2022 midpoint sits below the 2021 peak of 6, and growth has not levelled off through the most recent partial year.
- One cluster dominates the citation table. three of the five most-cited records are occlusion-detection filings from a single lineage, with the earliest pulling 151 citations.
- Filing is US-centred but not US-exclusive. the United States leads with 15 receiving-office filings, ahead of Europe, India and the WIPO/PCT route, each in the single digits.
Filing growth compares 2021 (6 records) with 2024 (0) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 35 records in scope (CR5), not by the ranked leaders only.
What the patent record covers
This landscape tracks 35 patent families filed against insulin pump reliability and durability — delivery accuracy, occlusion detection, pump reliability and battery longevity — inside the core infusion-hardware IPC classes (A61M5/142, A61M5/168, A61M5/50). Nearly all records sit in A61M, the body-fluid delivery class, but a meaningful share cross into G16H healthcare informatics and A61B diagnosis, which signals that reliability claims increasingly lean on software-side monitoring rather than mechanical hardening alone.
Publication lags filing by roughly 18 months, so the 2025–2026 count in the trend chart understates real filing activity for those years. Read the recent-year figures as a floor, not a ceiling.
Filing trend and technology mix
Two views of the same 35-family set: how filing volume has moved year over year, and which IPC subclasses carry the claim weight.
Filing trend, 2017–2026
Filings rose from 1 in 2017 to a peak of 6 in 2021, dipped to 1 at the 2022 midpoint, and are running at 3 in the most recent (partial) year — consistent with continued, not yet plateaued, growth once the reporting lag is accounted for.
IPC composition
A61M carries all 35 records as the anchor class. G16H (14) and A61B (7) show reliability claims are moving toward sensor-fused and software-monitored designs; G01L (4) and H05K (2) mark smaller, more mechanical or electronics-packaging niches.
Shares are the percentage of the 35 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Insulin Pump Reliability and Durability with Eureka
This page is one run against one query. Ask Eureka your own question about insulin pump reliability and durability and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records
Artificial pancreas integrated CGM architectures and designs
A system for managing a patient's glucose level includes a glucose sensor to generate and store data signals for measurements of the patient's glucose level made by the glucose sensor; an insulin pump; and sensor electronics operatively coupled to the glucose sensor, the sensor electronics comprising a memory storing one or more predetermined characteristics associated with the sensor electronics; and a computing device in electronic communication with the sensor electronics.Filed by Abbott Diabetes Care Inc.; granted 2021-09-14.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20170216524A1 | Continuous glucose monitoring injection device | 151 |
| 2 | WO2016019192A1 | Continuous glucose monitoring injection device | 89 |
| 3 | US9173998B2 | System and method for detecting occlusions in an infusion pump | 43 |
| 4 | US20140276409A1 | System and method for detecting occlusions in an infusion pump | 40 |
| 5 | US9962486B2 | System and method for detecting occlusions in an infusion pump | 21 |
| 6 | US11116900B2 | Continuous glucose monitoring injection device | 14 |
| 7 | US20160051758A1 | System and method for detecting occlusions in an infusion pump | 12 |
| 8 | US10252002B2 | Continuous glucose monitoring injection device | 12 |
| 9 | US20190298920A1 | Continuous glucose monitoring injection device | 10 |
| 10 | WO2014158627A1 | System and method for detecting occlusions in an infusion pump | 10 |
Citation counts reflect influence within this searched corpus and skew toward older filings; treat them as a signal of what shaped the field, not of what is currently strongest.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say
Four read-outs from the family set, the citation table and the co-filing map.
Growth has not plateaued
The 2022 midpoint of 1 sits well below the 2021 peak, and the latest partial year is already back at 3. Given the ~18-month publication lag, actual 2025–2026 filing is likely higher than currently visible.
Occlusion detection anchors the citation table
Three of the five most-cited records trace to occlusion-detection filings from one lineage (US9173998B2, US20140276409A1, US9962486B2). New entrants in occlusion sensing are filing against dense, well-cited prior art.
Reliability is becoming a software claim
Nearly 40% of the family set touches G16H alongside A61M, meaning a growing share of reliability and durability claims are anchored in monitoring software and data architecture, not just mechanical design.
Collaboration is thin and mostly bilateral
The strongest pairing appears twice; the rest occur once each. This is a field of largely independent filers rather than dense joint-development networks.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to insulin pump reliability and durability, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Roche Diabetes Care GmbH | F. Hoffmann-La Roche Ltd | 2 |
| DEKA Research & Development / Tandem Medical LLC | YODFAT OFER | 1 |
| DEKA Research & Development / Tandem Medical LLC | SHSTREETCAR LIOR | 1 |
| DEKA Research & Development / Tandem Medical LLC | SCNELL AMIT | 1 |
| DEKA Research & Development / Tandem Medical LLC | PALERMO GIUSEPPE | 1 |
| DEKA Research & Development / Tandem Medical LLC | MAIFREDI MARCO | 1 |
| DEKA Research & Development / Tandem Medical LLC | GANZITTI GABRIELE | 1 |
| DEKA Research & Development / Tandem Medical LLC | GAD MORAN | 1 |
Ten identified co-assignee pairs, none appearing more than twice — collaboration exists but is not structurally central to how this space is being claimed.
Who is filing, and where the gaps sit
Recent-year momentum is thin and spread across several assignees rather than concentrated in one leader, with a long tail of single-filing entrants behind the named players.
Abbott Diabetes Care Inc. / Abbott Diabetes Care
Filed the top-cited representative record on artificial-pancreas CGM architecture and shows continued, if modest, recent-year activity.
DEKA Research & Development / Tandem Medical LLC
Holds a co-assignee pairing with individual inventors YODFAT OFER and SHSTREETCAR LIOR, and maintains flat but non-zero recent-year filing.
Becton, Dickinson and Company (BD) / Becton Dickinson
No latest-year filings recorded here, despite historical presence in the occlusion-detection cluster that anchors the citation table.
Tandem Diabetes Care, Inc. / Tandem Diabetes Care
Shows no recent-year filings in this dataset window, consistent with a pause rather than an exit given the short observation period.
| Assignee | Recent year | YoY |
|---|---|---|
| Abbott Diabetes Care Inc. | 1 | — |
| DEKA Research & Development / Tandem Medical LLC | 1 | 0% |
| YODFAT OFER | 1 | — |
| SHSTREETCAR LIOR | 1 | — |
| Becton, Dickinson and Company (BD) | 0 | — |
| Tandem Diabetes Care, Inc. | 0 | — |
| CERCACOR LABORATORIES INC | 0 | — |
| Roche Diabetes Care GmbH | 0 | — |
Where this goes from here
Two threads worth tracking as the 2025–2026 filing years fill in.
Watch the software crossover
With 14 of 35 families already touching G16H, reliability claims are migrating from mechanical hardening toward predictive and monitoring software. Expect the next filing wave to weight algorithmic occlusion and failure-prediction claims more heavily.
Explore G16H filingsTrack the occlusion-detection incumbents
The citation table's concentration around one lineage suggests that lineage's continuations are worth monitoring closely for scope creep before filing adjacent claims.
Review citation leadersCommon questions
This landscape identifies 35 patent families published between 2015 and mid-2026 that match the combined search on insulin pump/delivery/artificial pancreas terms with delivery-accuracy, occlusion-detection, pump-reliability or battery-longevity claim language, restricted to the core A61M5/142, A61M5/168 and A61M5/50 IPC classes. Because publication lags filing by roughly 18 months, the true count for 2025–2026 filings is understated in any snapshot taken today. Families, rather than raw document counts, are the more reliable unit here because they neutralise duplicate continuations and multi-jurisdiction refilings of the same invention.
The United States receives the most filings in this dataset, with 15 records, followed by Europe (EPO) at 7 and India and WIPO/PCT each at 6. Canada trails with a single filing. This distribution reflects the US as the primary commercial market for insulin pump manufacturers, with the EPO and PCT routes used for parallel international coverage rather than as primary filing venues.
Occlusion detection covers sensing methods that identify a blocked or restricted insulin delivery line before it causes an under-dosing event. In this dataset, three of the five most-cited records are occlusion-detection filings from a single lineage, led by a patent cited 151 times, which indicates this sub-area shaped much of the subsequent claim language in the field. New filers targeting occlusion sensing should expect to design around dense, well-established prior art rather than open claim space.
High filing density in occlusion detection and delivery accuracy means that specific claim space is occupied, not that the underlying technology problem is solved. Sub-areas such as battery-longevity failure prediction, printed-circuit packaging for wearable pump form factors, and cross-device CGM-pump data architecture show comparatively thin family counts relative to the core clusters. These pockets are worth scoping closely before assuming freedom to operate, since thin filing counts can also reflect early-stage technical difficulty rather than open opportunity.
Recent-year momentum in this dataset is thin and split across a handful of assignees rather than concentrated in one leader — Abbott Diabetes Care and a Tandem-lineage filer each show a single filing in the latest year. Becton Dickinson and Tandem Diabetes Care appear in the historical citation cluster but show no latest-year filings here, which may reflect a pause in this specific claim area rather than a broader exit. Co-assignee filing is limited to 10 pairs across the whole set, so this remains a field of largely independent filers.
Research Insulin Pump Reliability and Durability in depth with Eureka
Go past this page: query the whole insulin pump reliability and durability corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.